Lifeward Ltd. Q4 FY2025 earnings call

Mark started by discussing the company's strategy to build a leading diversified biomedical innovation company. The pending close of the strategic agreement with Oramed was an important milestone, which strengthens the financial foundation. ORMP 0801, an oral insulin candidate, has potential benefits. The acquisition of intellectual property and technology from Scalable for a powered upper extremity orthotic system was mentioned. The core neuro rehab business made progress in reimbursement, clinical partnerships, and global distribution but had revenue issues due to sales and distribution infrastructure changes and Ultra-G sales decline. The company has multiple next - generation technologies in development.

Revenue for the year ended December 31st, 2025 was $22 million compared to $25.7 million in 2024, a decrease of approximately 14%. Revenue from the sales of Rework Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024. Revenue of the motorcycle FES bike declined by 50% to $600,000. Revenue from the sales of AlterG products and services was $12.9 million, a decline of 18% from 2024. Gross profit increased in 2025 to $8.4 million, or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024. Operating expenses declined by 25% to $28.1 million in 2025, compared to $37.6 million in 2024. Operating loss narrowed by 33% in 2025 to $19.7 million compared to $29.3 million in 2024. Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024. Operating cash usage was reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024

Given the significant transformation and pending close of the agreement with Oramed, no guidance is provided at this time. The company remains excited about long - term prospects and cautiously optimistic about growth in the core MedTech business with continued improvements in operating expenses helping drive toward positive cash flow in the near future

Q: About the Oramed Pot technology, how much work needed before approval and how it aligns with commercial infrastructure; Q: About the upper extremity robotic assistance, specific timeline of study, regulatory process, and market benefits over competitors; Q: Broad - level question about the company's move into multiple areas and if it's a concern; Q: What drove additional execution and future outlook; Q: Quantifying backlog as entering 2026